Results 121 to 130 of about 1,774 (147)
Some of the next articles are maybe not open access.
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
PediatricsBACKGROUND Data describing respiratory syncytial virus (RSV) neutralizing antibody (nAb) levels for nirsevimab, a recently approved, extended half-life, anti-RSV fusion protein (F protein) monoclonal antibody, relative to the previous standard of care, palivizumab ...
Deidre, Wilkins +9 more
openaire +2 more sources
Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants
NEJM EvidenceIn pivotal trials, nirsevimab showed promising efficacy in reducing hospitalizations for respiratory syncytial virus-associated lower respiratory tract infections (RSV-LRTIs). Nirsevimab's real-world effectiveness needs to be assessed.This population-based study used the French National Health Data System.
Marie Joelle, Jabagi +4 more
openaire +2 more sources
Safety of timely immunization with nirsevimab in hospitalized preterm infants
VaccineWe aimed to assess the safety profile of nirsevimab in hospitalized preterm infants (PT). We conducted an observational, uncontrolled, prospective study in clinically stable PT admitted to the neonatal unit. One hundred and ten PT were eligible for immunization; uptake was 93.5 % (n = 103) (median GA and BW of 33 weeks and 1892 g, respectively), and a ...
Giannina, Izquierdo +6 more
openaire +2 more sources